Hulk wrote, frankly, those who were negative were
Post# of 148057
(Total Views: 1670)
Posted On: 10/29/2021 3:05:50 AM
Hulk wrote,
Actually, quite a lot of great things happened this year. It is true that CD10 and CD12 got so-so results -- though better than any other treatment -- and true the FDA decided to publish its bizarre and untrue broadside. But don't mistake the decline in SP for a lack of progress.
In the last year CYDY has gotten great early results from its breast cancer trial.
In the last year the company has designed and gotten approval for a Covid Long-Hauler trial, which is about to start. It's designed and gotten approval and started a pair of sizeable trials for Covid in Brazil. It's gotten a lot of good results and some press for prominent results in the Philippines. Essentially it's broadened operations to become a global company.
It's also hired Dr. Recknor, who's pinpointed the mistakes Amarex has made, and gotten rid of same, and begun the process of correcting them.
It's fought off an attack to take over the company by the main owners of Incelldx. It's developed the strength and legal acumen to become something other than a patsy.
It's grown a lot.
It's only the share price that has messed up this year, and a lot of that has been due to the recurring attacks from the "activist"-slash-thief group.
If you're selling, it's been a disaster. If you're holding, it's just been a matter of a longer wait. If you're buying, it's been a godsend.
Quote:
frankly, those who were negative were the only ones who got it right over the past year - unless i'm missing the positives in an 80% decline in value.
Actually, quite a lot of great things happened this year. It is true that CD10 and CD12 got so-so results -- though better than any other treatment -- and true the FDA decided to publish its bizarre and untrue broadside. But don't mistake the decline in SP for a lack of progress.
In the last year CYDY has gotten great early results from its breast cancer trial.
In the last year the company has designed and gotten approval for a Covid Long-Hauler trial, which is about to start. It's designed and gotten approval and started a pair of sizeable trials for Covid in Brazil. It's gotten a lot of good results and some press for prominent results in the Philippines. Essentially it's broadened operations to become a global company.
It's also hired Dr. Recknor, who's pinpointed the mistakes Amarex has made, and gotten rid of same, and begun the process of correcting them.
It's fought off an attack to take over the company by the main owners of Incelldx. It's developed the strength and legal acumen to become something other than a patsy.
It's grown a lot.
It's only the share price that has messed up this year, and a lot of that has been due to the recurring attacks from the "activist"-slash-thief group.
If you're selling, it's been a disaster. If you're holding, it's just been a matter of a longer wait. If you're buying, it's been a godsend.
(34)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼